10-Q: SRx Health Solutions Shifts to Pet Health, Raises Capital

SRx Health Solutions reports Q1 2026 results, focusing on its Halo pet health business after discontinuing Canadian healthcare operations, while securing significant new financing.

Summary

• SRx Health Solutions Inc. (formerly Better Choice Company, Inc.) has fully transitioned its business, discontinuing its Canadian pharmacy and healthcare services (SRx Canada) and now operating solely through its premium pet health and nutrition products segment, Halo, Purely for Pets, Inc.
• For the three months ended December 31, 2025, net sales from continuing operations (Halo) were $2.807 million, with a gross profit of $1.054 million, representing a 38% gross margin.
• The company reported a net loss from continuing operations of $8.614 million for the quarter, compared to a net loss of $3.983 million in the prior year (which included discontinued operations).
• Cash and cash equivalents significantly increased to $13.060 million as of December 31, 2025, up from $1.309 million on September 30, 2025, primarily due to financing activities.
• Key financing activities included $16.094 million from common stock issuance and $8.912 million from preferred stock issuance, partially offset by $1.623 million in convertible debt repayment.
• The company recognized a $3.064 million loss on extinguishment of debt related to the settlement of July 2025 convertible notes.
• Digital assets held by the company, including Ethereum and Bitcoin, were valued at $7.996 million as of December 31, 2025, with a change in fair value resulting in a $464 thousand loss for the quarter.
• SRx Canada initiated restructuring proceedings under the Companies Creditors Arrangement Act (CCAA) in Canada on August 12, 2025, which exclusively relates to the discontinued healthcare business.
• The company entered into an amended Common Share Purchase Agreement (ELOC) on October 28, 2025, increasing the total commitment from $50 million to $1.0 billion, and issued a $20.0 million ELOC Commitment Note.
• Subsequent to the quarter, the company issued 211,226,000 shares of common stock under the ELOC Purchase Agreement for approximately $29.1 million.
• The NYSE American accepted the company's plan to regain compliance with listing standards on January 6, 2026, granting an extension until July 14, 2026.
• The company entered into an agreement on December 16, 2025, to acquire EMJ Crypto Technologies Inc. and DelawareCo, and certain intellectual property assets, for approximately $55 million in an all-stock transaction.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the significant capital raises and strategic focus on the pet health business are positive steps towards stabilization, the substantial net losses, negative Adjusted EBITDA, and high customer/supplier concentration indicate ongoing operational challenges and financial vulnerability.

Positives

• Cash and cash equivalents increased significantly to $13.060 million as of December 31, 2025, from $1.309 million on September 30, 2025, indicating improved liquidity.
• Successful capital raises through common stock issuance ($16.094 million) and preferred stock issuance ($8.912 million) during the quarter.
• The NYSE American accepted the company's plan to regain compliance with listing standards, providing an extension until July 14, 2026, which temporarily alleviates delisting concerns.
• The strategic shift to focus solely on the premium pet health and nutrition products segment (Halo) provides a more streamlined operating footprint and reduced overhead compared to the previous capital-intensive healthcare model.
• The company acquired 100% ownership of Halo, Purely for Pets, Inc. on August 21, 2025, consolidating its core continuing business.

Negatives

• Reported a net loss from continuing operations of $8.614 million for the three months ended December 31, 2025.
• Incurred a $3.064 million loss on extinguishment of debt related to the settlement of the July 2025 convertible notes.
• Experienced a $464 thousand loss from the change in fair value of digital assets during the quarter, highlighting volatility in this asset class.
• Adjusted EBITDA for the quarter was negative $1.057 million, indicating ongoing operational losses even after adjustments.
• The company continues to incur significant selling, general, and administrative expenses ($4.844 million) relative to its net sales ($2.807 million).
• The discontinuation of the SRx Canada healthcare business involved CCAA restructuring proceedings, indicating financial distress in that segment.

Risks

• The company's digital asset holdings expose it to significant legal, commercial, regulatory, and technological uncertainties, including extreme price volatility, counterparty risk, and cybersecurity threats.
• Concentration risk exists with major suppliers (98% of inventory purchases from two vendors) and major customers (96% of accounts receivable and 88% of gross sales from two customers), making the company vulnerable to changes with these parties.
• The company has historically incurred operating losses and negative operating cash flows, raising concerns about its ability to achieve or maintain profitability and generate sufficient cash flow.
• Potential price increases and shortages on inputs, commodities, and ingredients due to broader geopolitical and macroeconomic conditions, including the military conflict between Russia and Ukraine, could impact gross margins.
• The company's ability to successfully implement its growth strategy, develop additional products, and attract/retain customers in a competitive market is crucial for future success.
• Allegations that products cause injury or illness, or failure to comply with government regulations (FDA, FTC, USDA), could lead to product recalls and damage brand reputation.
• The regulatory environment for digital assets is evolving, and future legislative or regulatory actions could impact the company's ability to hold, transfer, or dispose of these assets.
• The company is subject to liquidity risk related to its financial liabilities, including trade payables and convertible debt, despite recent financing activities.
• The valuation of derivative liabilities and equity-linked instruments involves significant management judgment and subjective assumptions, which may lead to material non-cash volatility in reported results.

Future Outlook

Management's outlook reflects the early stages of a business reset, with near-term priorities focused on strengthening the financial position of the continuing Halo operations, optimizing the cost structure, and re-establishing a focused growth path. The company will continue evaluating strategic alternatives, including potential partnerships, product expansion opportunities, and targeted investments, to support long-term viability.

Management Comments

• "Management believes that the streamlined business provides a clearer path to operational stability and disciplined execution."
• "The Company will continue evaluating strategic alternatives to support the long-term viability of the business, including potential partnerships, product expansion opportunities, and targeted investments that align with the strengths of the continuing operations."
• "We continue to work with co-manufacturing and freight partners to realize future cost savings and improved gross margins."
• "Gross margins may continue to fluctuate due to inflationary pressures on transportation and raw material costs."
• "We will continue to refine and optimize our pricing strategy to align with market conditions and manage cost pressures."

Industry Context

StockSavvy.ai notes that the pet health and nutrition market is a growing sector, often resilient to economic downturns, driven by increasing pet ownership and humanization of pets. The company's focus on premium and super-premium products aligns with a key trend of consumers seeking higher quality, science-based nutrition for their pets. However, the market is competitive, with established players and new entrants, requiring continuous innovation and strong brand awareness. The company's foray into digital assets, while potentially offering diversification, introduces exposure to the highly volatile and evolving cryptocurrency market, which is distinct from its core pet health business.

Comparison to Industry Standards

• The 38% gross margin for the Halo pet health business is within the typical range for premium pet food brands, which can vary from 30% to 50% depending on product mix, distribution channels, and ingredient costs. For example, Blue Buffalo (General Mills) often reports gross margins in the mid-to-high 30s, while smaller, specialized brands might achieve higher margins.
• The significant net loss and negative Adjusted EBITDA indicate that the company's continuing operations are not yet profitable, which is below industry standards for established, profitable pet food companies like Mars Petcare or Nestlé Purina. However, for a company undergoing a major restructuring and focusing on growth, initial losses are not uncommon.
• The high concentration of sales and accounts receivable with two customers (88% of gross sales, 96% of receivables) is significantly higher than industry benchmarks for diversified consumer product companies, which typically aim for no single customer to exceed 10-15% of revenue to mitigate risk. This concentration is a notable vulnerability compared to peers like Chewy or Petco, which have broad customer bases.
• The company's substantial capital raises, including the $1.0 billion ELOC commitment, suggest a need for significant funding to stabilize and grow the business, which could be higher than typical for a company of its current revenue scale, potentially indicating a more challenging financial position or ambitious growth plans compared to more mature, self-funding industry players.

Management Changes

Corporate Governance

Legal Proceedings

• SRx Canada initiated restructuring proceedings under the Companies Creditors Arrangement Act (CCAA) in Canada on August 12, 2025, which relates exclusively to the discontinued SRx healthcare business.
• The company is subject to litigation and other proceedings that arise in the ordinary course of business, but management believes no pending lawsuits or claims will have a material adverse effect on its business, financial condition, or yearly results of operations.

Related Party Transactions

• As of December 31, 2025, certain members of the Board of Directors held outstanding convertible promissory notes totaling $0.5 million, bearing 8% interest per annum.
• For the three months ended December 31, 2025, continuing operations incurred approximately $0.6 million in director fees.
• During the three months ended December 31, 2025, the company issued an aggregate of $1.0 million in share-based compensation to its directors and executive officers.
• Executive officers received an aggregate of $0.6 million in compensation during the three months ended December 31, 2025, pursuant to their employment arrangements.

Stakeholder Impact

• **Shareholders**: Significant dilution from recent and planned equity issuances (ELOC, PIPE financings) and potential future reverse stock split. The strategic shift to pet health and capital raises aim to stabilize the business, but ongoing losses and NYSE compliance issues create uncertainty.
• **Employees**: The discontinuation of SRx Canada's healthcare business likely resulted in job losses in that segment. The focus on Halo aims to provide stability for employees in the continuing operations.
• **Customers (Halo)**: The company's focus on product innovation and brand awareness in the pet health segment aims to maintain and attract customers. High customer concentration poses a risk if relationships with key customers deteriorate.
• **Suppliers**: High concentration of inventory purchases from two vendors creates dependency and potential risk if those relationships are disrupted.
• **Creditors**: The repayment of July 2025 convertible notes and the CCAA proceedings for SRx Canada impact creditors differently. New debt (ELOC Commitment Note) introduces new obligations and security interests.

Next Steps

• Regain compliance with NYSE American listing standards by July 14, 2026, with quarterly progress updates required.
• Continue to strengthen the financial position of the continuing Halo operations.
• Optimize cost structure and re-establish a focused growth path for the Consumer Products business.
• Evaluate strategic alternatives, including potential partnerships, product expansion opportunities, and targeted investments.
• Complete the acquisition of EMJ Crypto Technologies Inc. and DelawareCo for approximately $55 million in an all-stock transaction.
• Amend the ELOC Registration Statement to register an additional $972.45 million of Common Stock, subject to increased authorized capital.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation, divesting its unprofitable healthcare segment and focusing on its pet health business. While recent capital raises and the NYSE compliance extension provide crucial liquidity and stability, the company continues to report substantial net losses and negative Adjusted EBITDA. The high concentration of sales and supply chain with a few partners, coupled with the volatility of digital asset holdings, introduces considerable risk. Given the ongoing restructuring, the need for further operational improvements, and the inherent uncertainties, a 'hold' recommendation is appropriate. Investors should monitor progress on profitability, market share in the pet health segment, and the effective deployment of raised capital before considering a stronger position.

Keywords

Pet Health, Halo, Pet Food, Digital Assets, Cryptocurrency, Convertible Debt, Capital Raise, SEC Filing, 10-Q, SRx Health Solutions, Halo Purely for Pets, Corporate Restructuring, NYSE American Compliance